Page last updated: 2024-09-05

solifenacin succinate and Hypertension

solifenacin succinate has been researched along with Hypertension in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Cicione, A; DE Nunzio, C; DI Giacomo, F; Disabato, G; Franco, A; Gallo, G; Gravina, C; Lombardo, R; Nacchia, A; Rovesti, L; Trucchi, A; Tubaro, A; Turchi, B	1
Chang, HM; Chang, YC; Chen, HL; Chen, TC; Huang, WH; Juan, YS; Lee, HY; Pan, HF; Wang, YL; Wu, CM	1
Ivanovskaya, MA; Kosilov, KV; Kosilova, LV; Loparev, SA	1

Reviews

1 review(s) available for solifenacin succinate and Hypertension

Article	Year
Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis. World journal of urology, 2018, Volume: 36, Issue:8 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Hypertension; Male; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive; Urological Agents	2018

Article

Year

Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.

World journal of urology, 2018, Volume: 36, Issue:8

Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Female; Humans; Hypertension; Male; Muscarinic Antagonists; Randomized Controlled Trials as Topic; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Urinary Bladder, Overactive; Urological Agents

2018

Trials

1 trial(s) available for solifenacin succinate and Hypertension

Article	Year
Decrease of risk of developing symptoms of OAB in elderly men and women treated with loop diuretic for hypertensive disease using solifenacin. Current aging science, 2014, Volume: 7, Issue:3 Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Female; Furosemide; Humans; Hypertension; Inpatients; Longitudinal Studies; Male; Prospective Studies; Quinuclidines; Risk Factors; Russia; Sodium Potassium Chloride Symporter Inhibitors; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics	2014

Article

Year

Decrease of risk of developing symptoms of OAB in elderly men and women treated with loop diuretic for hypertensive disease using solifenacin.

Current aging science, 2014, Volume: 7, Issue:3

Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Female; Furosemide; Humans; Hypertension; Inpatients; Longitudinal Studies; Male; Prospective Studies; Quinuclidines; Risk Factors; Russia; Sodium Potassium Chloride Symporter Inhibitors; Solifenacin Succinate; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder, Overactive; Urodynamics

2014

Other Studies

1 other study(ies) available for solifenacin succinate and Hypertension

Article	Year
Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance Database. Minerva urology and nephrology, 2022, Volume: 74, Issue:6 Topics: Aged; Aged, 80 and over; Female; Humans; Hypertension; Male; Muscarinic Antagonists; Solifenacin Succinate; Tolterodine Tartrate; Urinary Bladder, Overactive; Urinary Retention	2022